{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-not-diabetic/diagnosis/investigations/","result":{"pageContext":{"chapter":{"id":"a6466983-7adb-5a4f-8864-f3ecc06b447a","slug":"investigations","fullItemName":"Investigations","depth":2,"htmlHeader":"<!-- begin field d3bd55a6-fa88-4a63-b099-aafa013ebc9d --><h2>What investigations should I arrange?</h2><!-- end field d3bd55a6-fa88-4a63-b099-aafa013ebc9d -->","summary":"","htmlStringContent":"<!-- begin item b0b8855a-9257-4cc3-bf33-aafa013ebc21 --><!-- begin field da44712d-1a02-4d0d-94e6-aafa013ebc9d --><ul><li><strong>Assess for target organ damage.</strong><ul><li>Test for haematuria.</li><li>Arrange measurement of:<ul><li>Urine albumin:creatinine ratio (to test for the presence of protein in the urine).</li><li>HbA1C (to test for diabetes).</li><li>Electrolytes, creatinine, and estimated glomerular filtration rate (to test for chronic kidney disease).</li></ul></li><li>Examine the fundi (for the presence of hypertensive retinopathy).</li><li>Arrange for a 12-lead electrocardiograph to be performed (to assess cardiac function and detect left ventricular hypertrophy).</li><li>Consider the need for specialist investigations in people with signs and symptoms suggesting target organ damage or a <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/diagnosis/investigations/#secondary-causes-of-hypertension\">secondary cause</a> of hypertension. </li></ul></li><li><strong>Assess cardiovascular risk.</strong><ul><li>Arrange measurement of serum total cholesterol and high-density lipoprotein (HDL) cholesterol. </li><li>Estimate the person's 10-year risk of developing cardiovascular disease (CVD) using the <a data-hyperlink-id=\"4756249f-6213-491f-9a49-aa0200a2c67a\" href=\"https://qrisk.org/three/\">QRISK</a> assessment tool. <ul><li>For information on the management of people with a 10-year cardiovascular risk of 10% or more (including prescribing statins and anti-platelet therapy), see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>, <a class=\"topic-reference external-reference\" href=\"/topics/lipid-modification-cvd-prevention/\">Lipid modification - CVD prevention</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/antiplatelet-treatment/\">Antiplatelet treatment</a>. </li></ul></li></ul></li></ul><!-- end field da44712d-1a02-4d0d-94e6-aafa013ebc9d --><!-- end item b0b8855a-9257-4cc3-bf33-aafa013ebc21 -->","topic":{"id":"c1c1e500-a3f1-5baa-8d5f-890b15f767cc","topicId":"8de59d12-a526-4ab9-8496-1fcb59d838ff","topicName":"Hypertension - not diabetic","slug":"hypertension-not-diabetic","lastRevised":"Last revised in September 2020","chapters":[{"id":"2f82c42a-b82b-549e-9b10-218d9f782bf8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a5985652-a8b7-51c0-b2d2-6836d4507f90","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"95f1a40b-c079-5c37-af45-5e0806a2bcae","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4f16b189-bff9-5dfe-82a9-fdd4cd035ab0","slug":"changes","fullItemName":"Changes"},{"id":"a4dad1ea-40da-5ed2-85b0-8b5ea72bc196","slug":"update","fullItemName":"Update"}]},{"id":"b0107535-58ec-5e22-ac3b-22ae41ade390","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f76e08e3-badc-526a-835f-8f549cc3f784","slug":"goals","fullItemName":"Goals"},{"id":"928c1147-d56a-5b8a-94f7-87ddad3ef460","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aae28613-e6a5-5ba1-b4fa-e5032a9918ac","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7bf8c570-8757-5ae3-802f-5cba9e5ceb86","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3ace22a3-d042-5a6a-9d63-3527cf484a0a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c1a38cc6-4765-5c16-9f08-592cfc9851a3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"066993d8-fd33-59fb-877b-6e8418b515d1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"15ade196-5491-5552-9df6-a17d4c9c69d7","slug":"definition","fullItemName":"Definition"},{"id":"4528059a-b33b-51d3-8c65-983b4c165a3a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3e698434-11c9-553c-96a6-a249bf121cbb","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"0bec257d-f02e-5030-a430-8accc5245e7f","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"e56e7d7e-9afc-5c38-a77a-8f2b80461457","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7dcedb3e-c4f4-55ff-9910-03ee5ed41bb4","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"a6466983-7adb-5a4f-8864-f3ecc06b447a","slug":"investigations","fullItemName":"Investigations"}]},{"id":"33227758-4699-5e51-be33-b22dca2eb654","fullItemName":"Management","slug":"management","subChapters":[{"id":"d6332f04-a86e-56ef-9e25-d77083a8371c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"92190a49-9e8d-5fae-93b2-cf6243cfc01b","slug":"angiotensin-converting-enzyme-inhibitors","fullItemName":"Angiotensin-converting enzyme inhibitors"},{"id":"5ee249d0-bc66-59a5-8138-2449798ff2eb","slug":"angiotensin-ii-receptor-blockers","fullItemName":"Angiotensin-II receptor blockers"},{"id":"115bec24-ba4e-5f2a-80dc-dee6e948a288","slug":"thiazide-type-diuretics","fullItemName":"Thiazide-type diuretics"},{"id":"2ae4ccdd-d119-5a5a-9c89-d6493f2552f2","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"44681f3b-7958-5edd-a944-eb440f1df250","slug":"spironolactone","fullItemName":"Spironolactone"},{"id":"cb9a67f7-3588-5c68-b3d5-6c63d50ad0b8","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"5740c79c-d5a7-5547-ab38-db87df2b9121","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"f3424e7c-5446-59b0-b50e-0724587bb306","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"3b3191c9-bff5-563f-b5c0-09e8a0d22441","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7d204db0-8ff2-556e-97b4-89516ac7819b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0f686cda-dcaf-5f12-b5d6-871aefae47fe","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"dfcaec55-3c23-5a3f-9c08-f151a3120dc2","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"804073cd-b49f-5e4a-bf85-90faf125ad0e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"613e4289-93db-5311-aa87-b5a7a6e82dd1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e42a873-c39f-5405-bf4f-efdd81187ea2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2b87bc1c-2b4a-556b-b320-6b4f18bcf85d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e56e7d7e-9afc-5c38-a77a-8f2b80461457","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"2581da0e-9aca-570c-a2fd-52b3e317cf6c","slug":"secondary-causes-of-hypertension","fullItemName":"Secondary causes of hypertension","depth":3,"htmlHeader":"<!-- begin field c45e6b7d-2b68-4a41-891b-ab090033833b --><h3>Secondary causes of hypertension</h3><!-- end field c45e6b7d-2b68-4a41-891b-ab090033833b -->","summary":null,"htmlStringContent":"<!-- begin item 8214c73e-e1dc-4f16-909b-ab0900338308 --><!-- begin field 363fee83-fca9-4e8d-ba93-ab090033833b --><ul><li><strong>Renal disorders are the most common cause of secondary hypertension. They include:</strong><ul><li>Chronic pyelonephritis — usually detected unexpectedly on ultrasonography when investigating hypertension.</li><li>Diabetic nephropathy — indicated by microalbuminuria or proteinuria.</li><li>Glomerulonephritis — often indicated by microscopic haematuria.</li><li>Polycystic kidney disease — suggested by an abdominal or flank mass, microscopic haematuria, or family history.</li><li>Obstructive uropathy — the person may have an abdominal or flank mass.</li><li>Renal cell carcinoma — classically the person may have haematuria, loin pain and a loin mass, but increasingly asymptomatic renal cell carcinoma is being picked up on ultrasonography or CT (computed tomography) scan. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/urological-cancers-recognition-referral/\">Urological cancers - recognition and referral</a>.</li></ul></li><li><strong>Other causes of secondary hypertension are:</strong><ul><li><strong>Vascular disorders, including:</strong><ul><li>Coarctation of the aorta — usually results in upper-limb hypertension. There can be a significant difference in blood pressure between the left and right arms. Other signs include absent or weak femoral pulses, radio-femoral delay, palpable collateral blood vessels in the back muscles, and a suprasternal murmur radiating through to the back.</li><li>Renal artery stenosis — suspect this if the person has peripheral vascular disease and an abdominal bruit, or if blood pressure is resistant to treatment. Most cases are clinically silent (other than hypertension), but the condition should be suspected if the plasma renin level is increased.</li></ul></li><li><strong>Endocrine disorders, including:</strong><ul><li>Primary hyperaldosteronism — probably the most common curable cause of hypertension. People usually present with hypokalaemia, alkalosis (elevated bicarbonate level), and plasma sodium level greater than 140 mmol/L, or a larger than expected decrease in serum potassium when using a low-dose thiazide-type diuretic. The symptoms may be non-specific, but rarely it may present with tetany, muscle weakness, nocturia, or polyuria. Treatment with a calcium-channel blocker can mask the features of primary hyperaldosteronism. After identification of a possible adrenal adenoma on CT scan or MRI (magnetic resonance imaging), tertiary referral is required for confirmation of unilateral aldosterone excess and possible laparoscopic adrenalectomy.</li><li>Phaeochromocytoma — people can present with intermittently high or labile blood pressure, or postural hypotension, headaches, sweating attacks, palpitations, or unexplained fever and abdominal pains. Alternatively, it can be asymptomatic. It is the rarest but most important cause of hypertension to diagnose because malignant transformation or catastrophic haemorrhage from the tumour can be fatal.</li><li>Cushing's syndrome — suspect this when clinical features are present (for example truncal obesity and striae). It rarely presents as hypertension alone.</li><li>Acromegaly — suspect this if clinical features are present (for example enlargement of hands and feet, facial changes, sweating).</li><li>Hypothyroidism — hypertension may result from altered levels of renin, angiotensin, and aldosterone, and is associated with an increased diastolic blood pressure. Clinical features may include fatigue, weight gain, dry skin and hair loss, constipation, and muscle weakness. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information.</li><li>Hyperthyroidism — increased systolic blood pressure may result. Clinical features may include tremor, anxiety, sweating, weight loss, diarrhoea, and heat intolerance. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hyperthyroidism/\">Hyperthyroidism</a> for more information.</li></ul></li><li><strong>Drugs and other substances, including:</strong><ul><li>Alcohol — misuse of alcohol may be the most common individual secondary cause of hypertension. Features include variable hypertension that is resistant to commonly used drugs and that disappears within a week or two of complete abstinence.</li><li>Ciclosporin.</li><li>Cocaine and other substances of abuse.</li><li>Combined oral contraceptive.</li><li>Corticosteroids.</li><li>Erythropoietin.</li><li>Leflunomide.</li><li>Liquorice — present in some herbal medicines.</li><li>Nonsteroidal anti-inflammatory drugs.</li><li>Sympathomimetics — may be found in over-the-counter cough and cold remedies (for example ephedrine and phenylpropanolamine).</li><li>Venlafaxine.</li></ul></li><li><strong>Other conditions, including:</strong><ul><li>Connective tissue disorders (scleroderma, systemic lupus erythematosus, polyarteritis nodosa).</li><li>Retroperitoneal fibrosis.</li><li>Obstructive sleep apnoea. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obstructive-sleep-apnoea-syndrome/\">Obstructive sleep apnoea syndrome</a> for more information.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">National Clinical Guideline Centre, 2011</a>]</p><!-- end field 363fee83-fca9-4e8d-ba93-ab090033833b --><!-- end item 8214c73e-e1dc-4f16-909b-ab0900338308 -->","subChapters":[]},{"id":"85812650-27c6-56d3-8175-49632553c53f","slug":"basis-for-recommendation-d82","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 969959cf-b8dc-4197-a96f-aafa0140faea --><h3>Basis for recommendation</h3><!-- end field 969959cf-b8dc-4197-a96f-aafa0140faea -->","summary":null,"htmlStringContent":"<!-- begin item d8250c8b-439a-42f8-aed7-aafa0140fad0 --><!-- begin field e8052110-f9f1-448e-9791-aafa0140faea --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Hypertension in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>]. For information on why NICE made these recommendations and how they might affect practice, see the section on <a href=\"https://www.nice.org.uk/guidance/ng136/resources/hypertension-in-adults-diagnosis-and-management-pdf-66141722710213\" data-hyperlink-id=\"25937438-2d7a-4a16-807c-aaf1006a82e7\">Rationale and impact</a> in the NICE guideline <em>Hypertension in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>].</p><!-- end field e8052110-f9f1-448e-9791-aafa0140faea --><!-- end item d8250c8b-439a-42f8-aed7-aafa0140fad0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}